School of Nursing and Public Health, University of Dodoma, PO Box 395, Dodoma, Tanzania.
President's Office-Regional Administration and Local Government, PO Box 1923, Dodoma, Tanzania.
AIDS Res Ther. 2023 Apr 13;20(1):22. doi: 10.1186/s12981-023-00515-1.
Despite substantial antiretroviral therapy (ART) coverage among individuals with human immunodeficiency virus (HIV) infection in Tanzania, viral load suppression (VLS) among HIV-positive children receiving ART remains intolerably low. This study was conducted to determine factors affecting the nonsuppression of VL in children with HIV receiving ART in the Simiyu region; thus, an effective, sustainable intervention to address VL nonsuppression can be developed in the future.
We conducted a cross-sectional study including children with HIV aged 2-14 years who were currently presenting to care and treatment clinics in the Simiyu region. We collected data from the children/caregivers and care and treatment center databases. We used Stata™ to perform data analysis. We used statistics, including means, standard deviations, medians, interquartile ranges (IQRs), frequencies, and percentages, to describe the data. We performed forward stepwise logistic regression, where the significance level for removal was 0.10 and that for entry was 0.05. The median age of the patients at ART initiation was 2.0 years (IQR, 1.0-5.0 years), and the mean age at HIV VL (HVL) nonsuppression was 8.8 ± 2.99 years. Of the 253 patients, 56% were female, and the mean ART duration was 64 ± 33.07 months. In multivariable analysis, independent predictors of HVL nonsuppression were older age at ART initiation (adjusted odds ratio [AOR] = 1.21; 95% confidence interval [CI] 1.012-1.443) and poor medication adherence (AOR, 0.06; 95% CI 0.004-0.867).
This study showed that older age at ART initiation and poor medication adherence play significant roles in HVL nonsuppression. HIV/AIDS programs should have intensive interventions targeting early identification, ART initiation, and adherence intensification.
尽管坦桑尼亚的艾滋病毒感染者接受了大量的抗逆转录病毒疗法(ART),但接受抗逆转录病毒疗法的艾滋病毒阳性儿童的病毒载量抑制(VLS)仍然低得令人无法接受。本研究旨在确定影响 Simiyu 地区接受抗逆转录病毒疗法的艾滋病毒儿童病毒载量未得到抑制的因素;因此,今后可以制定有效的、可持续的干预措施来解决病毒载量未得到抑制的问题。
我们进行了一项横断面研究,纳入了目前在 Simiyu 地区护理和治疗诊所就诊的 2-14 岁艾滋病毒儿童。我们从儿童/照顾者和护理治疗中心数据库中收集数据。我们使用 Stata™进行数据分析。我们使用统计数据,包括均值、标准差、中位数、四分位距(IQR)、频率和百分比来描述数据。我们进行了向前逐步逻辑回归,剔除标准为 0.10,纳入标准为 0.05。ART 开始时患者的中位年龄为 2.0 岁(IQR,1.0-5.0 岁),HIV 病毒载量(HVL)未得到抑制的平均年龄为 8.8±2.99 岁。在 253 名患者中,56%为女性,ART 持续时间的平均为 64±33.07 个月。在多变量分析中,HVL 未得到抑制的独立预测因素是 ART 开始时年龄较大(调整后的优势比 [AOR] = 1.21;95%置信区间 [CI] 1.012-1.443)和药物依从性差(AOR,0.06;95% CI 0.004-0.867)。
本研究表明,ART 开始时年龄较大和药物依从性差在 HVL 未得到抑制中起着重要作用。艾滋病毒/艾滋病规划应采取强化干预措施,以针对早期识别、ART 开始和依从性强化。